Yglesio Moyses de Souza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yglesio Moyses de Souza has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Abel H. Murakami
Gastro Obeso Center
1 shared publicationAlmino C. Ramos
Gastrointestinal, Bariatric and Metabolic Surgery, Gastro Obeso Center, São Paulo, Brazil
1 shared publicationAndrey C. Silva
Gastro Obeso Center
1 shared publicationBelchor Fontes
I Faculdade de Medicina da Universidade de São Paulo - São Paulo/SP, Brazil
1 shared publicationEdwin G. Canseco
Gastro Obeso Center
1 shared publicationGlacus S. Brito
I Faculdade de Medicina da Universidade de São Paulo - São Paulo/SP, Brazil
1 shared publication
Latest Publications
- Open Access
Evaluation of the effects of ozone therapy in the treatment of intra-abdominal infection in rats
- 6 November 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 19 (3) , 307-312
Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2 (LBMI)
The association between medical and dietetic–behavioral treatments of type 2 diabetes mellitus (T2DM) has demonstrated to have variable results. The surgical treatment of T2DM is justifiable after the observation of a successful glycemic control in patients submitted to Roux-en-Y gastric bypass and biliopancreatic diversion. Experiments have shown an important role of the proximal intestine in glycemia decrease and diabetes control. Twenty diabetic patients underwent laparoscopic duodenal–jejunal exclusion. The variables studied were body mass index (BMI), fasting glycemia, glycosylated hemoglobin (HbA1c), and C-peptide, in the preoperative period and after 3 and 6 months. There was a BMI decrease up to the third month and a weight stabilization between the third and sixth months. There was a significant reduction in fasting glycemia (43.8%) and HbA1c (22.8%) up to the sixth month (p < 0.001). C-peptide did not show any significant alteration until the third month, although there was a considerable increase (25%) between the third and the sixth months (p < 0.001). Only two patients were on oral medication after the sixth month. Preliminary results have shown an important effect of the laparoscopic duodenal–jejunal exclusion in the treatment of T2DM. Studies with longer follow-up and a larger number of patients are necessary to better define the role of this new and promising procedure.
- 6 November 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 19 (3) , 307-312
Laparoscopic Duodenal–Jejunal Exclusion in the Treatment of Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2 (LBMI)
The association between medical and dietetic–behavioral treatments of type 2 diabetes mellitus (T2DM) has demonstrated to have variable results. The surgical treatment of T2DM is justifiable after the observation of a successful glycemic control in patients submitted to Roux-en-Y gastric bypass and biliopancreatic diversion. Experiments have shown an important role of the proximal intestine in glycemia decrease and diabetes control. Twenty diabetic patients underwent laparoscopic duodenal–jejunal exclusion. The variables studied were body mass index (BMI), fasting glycemia, glycosylated hemoglobin (HbA1c), and C-peptide, in the preoperative period and after 3 and 6 months. There was a BMI decrease up to the third month and a weight stabilization between the third and sixth months. There was a significant reduction in fasting glycemia (43.8%) and HbA1c (22.8%) up to the sixth month (p < 0.001). C-peptide did not show any significant alteration until the third month, although there was a considerable increase (25%) between the third and the sixth months (p < 0.001). Only two patients were on oral medication after the sixth month. Preliminary results have shown an important effect of the laparoscopic duodenal–jejunal exclusion in the treatment of T2DM. Studies with longer follow-up and a larger number of patients are necessary to better define the role of this new and promising procedure.